These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

173 related items for PubMed ID: 10212129

  • 1. Potent, low-molecular-weight non-peptide inhibitors of malarial aspartyl protease plasmepsin II.
    Haque TS, Skillman AG, Lee CE, Habashita H, Gluzman IY, Ewing TJ, Goldberg DE, Kuntz ID, Ellman JA.
    J Med Chem; 1999 Apr 22; 42(8):1428-40. PubMed ID: 10212129
    [Abstract] [Full Text] [Related]

  • 2. De Novo design, synthesis, and in vitro evaluation of a new class of nonpeptidic inhibitors of the malarial enzyme plasmepsin II.
    Carcache DA, Hörtner SR, Bertogg A, Binkert C, Bur D, Märki HP, Dorn A, Diederich F.
    Chembiochem; 2002 Nov 04; 3(11):1137-41. PubMed ID: 12404641
    [No Abstract] [Full Text] [Related]

  • 3. Identification of potent inhibitors of Plasmodium falciparum plasmepsin II from an encoded statine combinatorial library.
    Carroll CD, Patel H, Johnson TO, Guo T, Orlowski M, He ZM, Cavallaro CL, Guo J, Oksman A, Gluzman IY, Connelly J, Chelsky D, Goldberg DE, Dolle RE.
    Bioorg Med Chem Lett; 1998 Sep 08; 8(17):2315-20. PubMed ID: 9873534
    [Abstract] [Full Text] [Related]

  • 4. New benzimidazole derivatives as antiplasmodial agents and plasmepsin inhibitors: synthesis and analysis of structure-activity relationships.
    Saify ZS, Azim MK, Ahmad W, Nisa M, Goldberg DE, Hussain SA, Akhtar S, Akram A, Arayne A, Oksman A, Khan IA.
    Bioorg Med Chem Lett; 2012 Jan 15; 22(2):1282-6. PubMed ID: 22204908
    [Abstract] [Full Text] [Related]

  • 5. Design and synthesis of potent inhibitors of the malaria aspartyl proteases plasmepsin I and II. Use of solid-phase synthesis to explore novel statine motifs.
    Johansson PO, Chen Y, Belfrage AK, Blackman MJ, Kvarnström I, Jansson K, Vrang L, Hamelink E, Hallberg A, Rosenquist A, Samuelsson B.
    J Med Chem; 2004 Jun 17; 47(13):3353-66. PubMed ID: 15189032
    [Abstract] [Full Text] [Related]

  • 6. High-speed optimization of inhibitors of the malarial proteases plasmepsin I and II.
    Nöteberg D, Schaal W, Hamelink E, Vrang L, Larhed M.
    J Comb Chem; 2003 Jun 17; 5(4):456-64. PubMed ID: 12857114
    [Abstract] [Full Text] [Related]

  • 7. Mechanism-based inhibitors of the aspartyl protease plasmepsin II as potential antimalarial agents.
    Gupta D, Yedidi RS, Varghese S, Kovari LC, Woster PM.
    J Med Chem; 2010 May 27; 53(10):4234-47. PubMed ID: 20438064
    [Abstract] [Full Text] [Related]

  • 8. New potent C2-symmetric malaria plasmepsin I and II inhibitors.
    Oscarsson K, Oscarson S, Vrang L, Hamelink E, Hallberg A, Samuelsson B.
    Bioorg Med Chem; 2003 Apr 03; 11(7):1235-46. PubMed ID: 12628651
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Macrocyclic inhibitors of the malarial aspartic proteases plasmepsin I, II, and IV.
    Ersmark K, Nervall M, Gutiérrez-de-Terán H, Hamelink E, Janka LK, Clemente JC, Dunn BM, Gogoll A, Samuelsson B, Qvist J, Hallberg A.
    Bioorg Med Chem; 2006 Apr 01; 14(7):2197-208. PubMed ID: 16307884
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Insight into selectivity of peptidomimetic inhibitors with modified statine core for plasmepsin II of Plasmodium falciparum over human cathepsin D.
    Dali B, Keita M, Megnassan E, Frecer V, Miertus S.
    Chem Biol Drug Des; 2012 Apr 01; 79(4):411-30. PubMed ID: 22129033
    [Abstract] [Full Text] [Related]

  • 13. Potent inhibitors of the Plasmodium falciparum enzymes plasmepsin I and II devoid of cathepsin D inhibitory activity.
    Ersmark K, Feierberg I, Bjelic S, Hamelink E, Hackett F, Blackman MJ, Hultén J, Samuelsson B, Aqvist J, Hallberg A.
    J Med Chem; 2004 Jan 01; 47(1):110-22. PubMed ID: 14695825
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Identification and characterization of allophenylnorstatine-based inhibitors of plasmepsin II, an antimalarial target.
    Nezami A, Luque I, Kimura T, Kiso Y, Freire E.
    Biochemistry; 2002 Feb 19; 41(7):2273-80. PubMed ID: 11841219
    [Abstract] [Full Text] [Related]

  • 17. [Selective inhibitors of plasmepsin II from Plasmodium falciparum based on pepstatin].
    Rumsh LD, Mikhaĭlova AG, Mikhura IV, Prudchenko IA, Chikin LD, Mikhaleva II, Kaliberda EN, Dergousova NI, Mel'nikov EE, Formanovskiĭ AA.
    Bioorg Khim; 2008 Feb 19; 34(6):739-46. PubMed ID: 19088746
    [Abstract] [Full Text] [Related]

  • 18. Identification of plasmepsin inhibitors as selective anti-malarial agents using ligand based drug design.
    McKay PB, Peters MB, Carta G, Flood CT, Dempsey E, Bell A, Berry C, Lloyd DG, Fayne D.
    Bioorg Med Chem Lett; 2011 Jun 01; 21(11):3335-41. PubMed ID: 21531557
    [Abstract] [Full Text] [Related]

  • 19. Additional interaction of allophenylnorstatine-containing tripeptidomimetics with malarial aspartic protease plasmepsin II.
    Hidaka K, Kimura T, Tsuchiya Y, Kamiya M, Ruben AJ, Freire E, Hayashi Y, Kiso Y.
    Bioorg Med Chem Lett; 2007 Jun 01; 17(11):3048-52. PubMed ID: 17400453
    [Abstract] [Full Text] [Related]

  • 20. Identification of acridinyl hydrazides as potent aspartic protease inhibitors.
    Azim MK, Ahmed W, Khan IA, Rao NA, Khan KM.
    Bioorg Med Chem Lett; 2008 May 01; 18(9):3011-5. PubMed ID: 18417344
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.